Integrin antagonists as therapeutics for inflammatory diseases

Expert Opinion on Investigational Drugs

Volumn 15, Issue 10, 2006, Pages 1235-1255

  Vanderslice, Peter ^a   Woodside, Darren G ^a  

^a TEXAS BIOTECHNOLOGY CORPORATION   (United States)

Author keywords

4 7; 1 2; 1 1; 2 1; 4 1; Asthma; Crohn's disease; Integrin; LFA 1; Lymphocyte; Psoriasis; Rheumatoid arthritis; Ulcerative colitis; VLA 4

Indexed keywords

ALPHA4 INTEGRIN; AQC 2; AZATHIOPRINE; BETA1A INTERFERON; BETA2 INTEGRIN; BIO 1211; CDP 323; DW 908E; EFALIZUMAB; GLUCOCORTICOID; GW 559090; HM 1031; HMR 1031; IC 747; INFLIXIMAB; INTEGRIN; ISIS 107248; IVL 745; IVL 984; MLN 02; MONOCLONAL ANTIBODY; NATALIZUMAB; ODULIMOMAB; PROTEIN ANTIBODY; PROTEIN INHIBITOR; R 411; SCH 525663; TBC 4746; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERY LATE ACTIVATION ANTIGEN 4;

ALLERGIC RHINITIS; ASTHMA; CLINICAL TRIAL; CROHN DISEASE; DRUG DOSE REGIMEN; DRUG STRUCTURE; DRUG TARGETING; ENTERITIS; EOSINOPHILIA; GASTROINTESTINAL DISEASE; HUMAN; IMMUNE DEFICIENCY; INFLAMMATORY DISEASE; LUNG DISEASE; MULTIPLE SCLEROSIS; NONHUMAN; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROTEIN FAMILY; PSORIASIS; REPRODUCTIVE TOXICITY; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SKIN DISEASE; ULCERATIVE COLITIS;

ANIMALS; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; INTEGRINS;

EID: 33750256352     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.15.10.1235     Document Type: Review

References (202)

1. HYNES RO: Integrins: a family of cell surface receptors. Cell (1987) 48:549-554.
2. HEMLER ME, HUANG C, TAKADA Y, SCHWARZ L, STROMINGER JL, CLABBY ML: Characterization of the cell surface heterodimer VIA-4 and related peptides. J. Biol. Chem. (1987) 262:11478-11485.
3. HYNES RO: Integrins: bidirectional, allosteric signaling machines. Cell (2002) 110:673-687.
4. RUOSLAHTI E: Integrins. J. Clin. Invest. (1991) 87:1-5.
5. SPRINGER TA: Adhesion receptors of the immune system. Nature (1990) 346:425-434.
6. 3. Science (2001) 294:339-345.
7. WHITTAKER CA, HYNES RO: Distribution and evolution of von Willebrand/ integrin A domains: widely dispersed domains with roles in cell adhesion and elsewhere. Mol. Biol. Cell (2002) 13:3369-3387.
8. SCHWARTZ MA, SCHALLER MD, GINSBERG MH: Integrins: emerging paradigms of signal transduction. Ann. Rev. Cell Dev. Biol. (1995) 11:549-599.
9. DUSTIN ML, SPRINGER TA: T-cell receptor cross-linking transiently stimulates adhesiveness through LFA-1. Nature (1989) 341:619-624.
10. CARMAN CV, SPRINGER TA: Integrin avidity regulation: are changes in affinity and conformation underemphasized? Curr. Opin. Cell Biol. (2003) 15:547-556.
11. BAZZONI G, HEMLER ME: Are changes in integrin affinity and conformation overemphasized? Trends Biochem. Sci. (1998) 23:30-34.
12. LAUDANNA C, KIM JY, CONSTANTIN G, BUTCHER E: Rapid leukocyte integrin activation by chemokines. Immunol. Rev. (2002) 186:37-46.
13. 3 in complex with an Arg-Gly-Asp ligand. Science (2002) 296:151-155.
14. 2 subunit I-like domain and activate signals in one direction and block them in the other. Immunity (2003) 19:391-402.
15. ARNAOUT MA, MAHALINGAM B, XIONG JP: Integrin structure, allostery, and bidirectional signaling. Ann. Rev. Cell Dev. Biol. (2005) 21:381-410.
16. FRELINGER AL III, COHEN I, PLOW EF et al.: Selective inhibition of integrin function by antibodies specific for ligand-occupied receptor conformers. J. Biol. Chem. (1990) 265:6346-6352.
17. 3 (glycoprotein IIb-IIIa) alter receptor affinity, specificity, and function. J. Biol. Chem. (1991) 266:17106-17111.
18. 1 Cell (2000) 101:47-56.
19. SHIMAOKA M, XIAO T, LIU JH et al.: Structures of the α L I domain and its complex with ICAM- 1 reveal a shape-shifting pathway for integrin regulation. Cell (2003) 112:99-111.
20. XIAO, T, TAKAGI J, COLLER BS, WANG JH, SPRINGER TA: Structural basis for allostery in integrins and binding to fibrinogen-mimetic therapeutics. Nature (2004) 432:59-67.
21. ELICES MJ, OSBORN L, TAKADA Y et al.: VCAM-1 on activated endothelium interacts with die leukocyte integrin VLA-4/fibronectin binding site. Cell (1990) 60:577-584.
22. 1. Eur. J. Biochem. (1993) 215:151-159.
23. 1, A-domain is a ligand binding site for collagens and laminin. J. Biol. Chem. (1997) 272:12311-12317.
24. 3 integrin stimulates immediate cell signals in osteoclasts. J. Biol. Chem. (1991) 266:20369-20374.
25. 5 promote adenovirus internalization but not virus attachment. Cell (1993) 73:309-319.
26. 1 integrin ligand invasin. J. Exp. Med. (1993) 177:207-212.
27. I to the ADAM-12 and -15 disintegrin domains mediates cell-cell interaction. J. Biol. Chem. (2000) 275:34922-34930.
28. 2 integrins. J. Biol. Chem. (2003) 278:34674-34684.
29. SCARBOROUGH RM, ROSE JW, NAUGHTON MA et al.: Characterization of the integrin specificities of disintegrins isolated from American pit viper venoms. J. Biol. Chem. (1993) 268:1058-1065.
30. SPRINGER TA: Folding of the N-terminal, ligand-binding region of integrin α-subunits into a β-propeller domain. Proc. Natl. Acad Sci. USA (1997) 94:65-72.
31. 1 integrin and Staphylococcus aureus cna MSCRAMM. J. Biol. Chem. (1999) 274:24906-24913.
32. PYTELA R: Amino acid sequence of the murine Mac-I α chain reveals homology with the integrin family and an additional domain related to von Willebrand factor. EMBO J. (1988) 7:1371-1378.
33. 2 integrin CR3 (Cd11b/CD18) is essential for ligand binding. Cell (1993) 72:857-867.
34. 2 integrin lymphocyte function-associated antigen-1 contains a binding site for ligand intercellular adhesion molecule-1. J. Biol. Chem. (1994) 269:12395-12398.
35. 2 integrin lymphocyte function-associated antigen-1. Mol. Biol. Cell (2000) 11:677-690.
36. YALAMANCHILI P. LU C, OXVIG C, SPRINGER TA: Folding and function of I domain-deleted Mac-1 and lymphocyte function- associated antigen-1. J. Biol. Chem. (2000) 275:21877-21882.
37. SHIMAOKA M, SPRINGER TA: Therapeutic antagonists and conformational regulation of integrin function. Nat. Rev. Drug Discov. (2003) 2:703-716.
38. 1 and ligand binding analysis. Biophys. J. (2002) 82:447-457.
39. KALLEN J, WELZENBACH K, RAMAGE P et al.: Structural basis for LFA-1 inhibition upon lovastatin binding to the CD11a I-domain. J. Mol, Biol. (1999) 292:1-9.
40. WEITZ-SCHMIDT G, WELZENBACH K, BRINKMANN V et al.: Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat. Med. (2001) 7:687-692.
41. 2 is sufficient for strong adhesive function when locked in the open conformation with a disulfide bond. Proc. Natl. Acad. Sci. USA (2001) 98:2387-2392.
42. 2 I domain with disulfide bonds reveals functional relationships among integrin domains. Proc. Natl. Acad. Sci. USA (2001) 98:2393-2398.
43. 2 integrin-mediated leukocyte cell adhesion by leucine-leucine-glycine motif-containing peptides. J. Cell Biol. (2001) 153:905-916.
44. BOCHNER BS, LUSCINSKAS FW, GIMBRONE MA et al.: Adhesion of human basophils, eosinophils, and neutrophils to interleukin 1-activated human vascular endothelial cells: contributions of endothelial cell adhesion molecules. J. Exp. Med. (1991) 173:1553-1557.
45. 1, -dependent adhesion pathway on neutrophils: a mechanism invoked by dihydrocytochalasin B or endothelial transmigration. FASEB J. (1995) 9:1103-1111.
46. ISSEKUTZ TB, MIYASAKA M, ISSEKUTZ AC: Rat blood neutrophils express very late antigen 4 and it mediates migration to arthritic joint and dermal inflammation. J. Exp. Med. (1996) 183:2175-2184.
47. 7, on human leukocytes. J. Immunol. (1994) 153:517-528.
48. P in lymphocyte adherence to fibronectin and VCAM-1 and in homotypic cell clustering. J. Cell Biol. (1992) 117:179-189.
49. WAYNER EA, GARCIA-PARDO A, HUMPHRIES MJ, McDONALD JA, CARTER WG: Identification and characterization of the T lymphocyte adhesion receptor for an alternative cell attachment domain (CS-1) in plasma fibronectin. J. Cell Biol. (1989) 109:1321-1330.
50. 7 integrin mediates lymphocyte binding to the mucosal vascular addressin madcam-1. Cell (1993) 74:185-195.
51. BRISKIN M, WINSOR-HINES D, SHYJAN A et al.: Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue. Am. J. Pathol. (1997) 151:97-110.
52. 4 integrin binding interfaces on VCAM-1 and MAdCAM-1. Integrin binding footprints identify accessory binding sites that play a role in integrin specificity. J. Biol. Chem. (1997) 272:19429-19440.
53. v-family integrins through novel integrin-binding mechanisms. Blood (2001) 98:458-466.
54. 1. Facilitation by JAM3. J. Biol. Chem. (2002) 277:27589-27592.
55. 1. J. Exp. Med. (1995) 182:345-355.
56. SANDBORN WJ, COLOMBEL JF, ENNS R et al.: Natalizumab induction and maintenance therapy for Crohn's disease. N. Engl. J. Med (2005) 353:1912-1925.
57. MILLER DH, KHAN OA, SHEREMATA WA et al.: A controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. (2003) 348:15-23.
58. POLMAN CH, O'CONNOR PW. HAVRDOVA E et al: A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. (2006) 354:899-910.
59. 4-integrins mediate antigen-induced late bronchial responses and prolonged airway hyperresponsiveness in sheep. J. Clin. Invest. (1994) 93:776-787.
60. 4 integrin) on intrapulmonary but not circulating leukocytes inhibits airway inflammation and hyperresponsiveness in a mouse model of asthma. J. Clin. Invest. (1997) 100:3083-3092.
61. 4 integrins in allergic airway responses and mast cell degranulation in vivo. Am. J. Respir. Crit. Care Med. (1998) 158:1127-1133.
62. METZGER WJ: Therapeutic approaches to asthma based on VLA-4 integrin and its counter receptors. Springer Semin. Immunopathol. (1995) 16:467-478.
63. PRETOLANI M, RUFFIE C, LAPA E SILVA JR, JOSEPH D, LOBB RR, VARGAFTIG BB: Antibody to very late activation antigen 4 prevents antigen-induced bronchial hyperreactivity and cellular infiltration in the guinea pig airways. J. Exp. Med. (1994) 180:795-805.
64. 7 integrin. N. Engl. J. Med (2005) 352:2499-2507.
65. 7. Gastroenterology (1996) 111:1373-1380.
66. KATO S, HOKARI R, MATSUZAKI K et al.: Amelioration of murine experimental colitis by inhibition of mucosal addressin cell adhesion molecule-1. J Pbarmacol. Exp. Ther. (2000) 295:183-189.
67. + T cells. J. Immunol. (1997) 158:2099-2106.
68. 4 integrin monoclonal antibody. J. Clin. Invest. (1993) 92:372-380.
69. SEIFFGE D: Protective effects of monoclonal antibody to VLA-4 on leukocyte adhesion and course of disease in adjuvant arthritis in rats. J. Rheumatol. (1996) 23:2086-2091.
70. WAHL SM, ALLEN JB, HINES KL et al.: Synthetic fibronectin peptides suppress arthritis in rats by interrupting leukocyte adhesion and recruitment. J. Clin. Invest. (1994) 94:655-662.
71. 1 blocks antigen-induced airway responses and inflammation in experimental asthma in sheep. Am. J. Respir. Crit. Care Med. (2000) 162:603-611.
72. KOO GC, SHAH K, DING GJ et al.: A small molecule very late antigen-4 antagonist can inhibit ovalbumin-induced lung inflammation. Am. J. Respir. Crit. Care Med. (2003) 167:1400-1409.
73. BURKLY LC, JAKUBOWSKI A, NEWMAN BM, ROSA MD, CHI-ROSSO G, LOBB RR: Signaling by vascular cell adhesion molecule-1 (VCAM-1) through VLA-4 promotes CD3-dependent T cell proliferation. Eur. J. Immunol. (1991) 21:2871-2875.
74. + T cells by the interaction of VLA-4 and VLA-5 with fibronectin or VLA-6 with laminin. J. Immunol. (1990) 145:59-67.
75. DIAMANT Z, KUPERUS J, BAAN R et al.: Effect of a very late antigen-4 receptor antagonist on allergen-induced airway responses and inflammation in asthma. Clin. Exp. Allergy (2005) 35:1080-1087.
76. NORRIS V, CHOONG L, TRAN D et al.: Effect of IVL745, a VLA-4 antagonist, on allergen-induced bronchoconstriction in patients with asthma. J. Allergy Clin. Immunol. (2005) 116:761-767.
77. 7 integrin antagonist after oral administration at single and multiple once-daily ascending doses in healthy volunteers. J. Clin. Pharmacol. (2004) 44:1368-1378.
78. LAFFON A, GARCIA-VICUNA R, HUMBRIA A, POSTIGO AA, CORBI AL: Upregulated expression and function of VLA-4 fibronectin receptors on human activated T cells in rheumatoid arthritis. J. Clin. Invest. (1991) 88:546-552.
79. 1, integrin (VLA-4) ligands in arthritis. Vascular cell adhesion molecule-1 expression in synovium and on fibroblast-like synoviocytes. J. Immunol. (1992) 149:1424-1431.
80. MULLER-LADNER U, ELICES MJ, KRIEGSMANN JB et al.: Alternatively spliced CS-1 fibronectin isoform and its receptor VLA-4 in rheumatoid arthritis synovium. J. Rheumatol. (1997) 24:1873-1880.
81. WELLICOME SM, KAPAHI P, MASON JC, LEBRANCHU Y, YARWOOD H, HASKARD DO: Detection of a circulating form of vascular cell adhesion molecule-1: raised levels in rheumatoid arthritis and systemic lupus erythematosus. Clin. Exp. Immunol. (1993) 92:412.
82. KITANI A, NAKASHIMA N, IZUMIHARA T et al.: Soluble VCAM-1 induces chemotaxis ofjurkat and synovial fluid cells bearing high affinity very late antigen-4. J. Immunol. (1998) 161:4931-4938.
83. KOCH AE, HALLORAN MM, HASKELL CJ, SHAH MR, POLVERINI PJ: Angiogenesis mediated by soluble forms of E-selectin and vascular cell adhesion molecule-1. Nature (1995) 376:517-519.
84. MITTELBRUNN M, MOLINA A, ESCRIBESE MM et al.: VLA-4 integrin concentrates at the peripheral supramolecular activation complex of the immune synapse and drives T helper 1 responses. Proc. Natl. Acad. Sci. USA (2004) 101:11058-11063.
85. BEDNARCZYK JL, TEAGUE TK, WYGANT JN, DAVIS LS, LIPSKY PE, McINTYRE BW: Regulation of T cell proliferation by anti-CD49d and anti-CD29 monoclonal antibodies. J. Leuk. Biol. (1992) 52:456-462.
86. + T cell activation via the CS1 alternatively spliced domain of fibronectin. J. Exp. Med. (1990) 172:1185-1192.
87. DAVIS LS, OPPENHEIMER MARKS N, BEDNARCZYK JL, McINTYRE BW, LIPSKY PE: Fibronectin promotes proliferation of naive and memory T cells by signaling through both the VLA-4 and VLA-5 integrin molecules. J. Immunol. (1990) 145:785-793.
88. 1-integrin-fibronectin adhesive interactions prevents chronic allograft rejection in sensitized recipients. Transplant. Proc. (1998) 30:939-940.
89. h2 cell regulation of murine cardiac allograft acceptance by blocking cell adhesion of ICAM-1/LFA-1 and VCAM-1/VLA-4. Transpl. Immunol. (1999) 7:65-72.
90. 1a, for multiple sclerosis. N. Engl. J. Med (2005) 353:369-374.
91. LANGER-GOULD A, ATLAS SW, GREEN AJ, BOLLEN AW, PELLETIER D: Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N. Engl. J. Med. (2005) 353:375-381.
92. VAN ASSCHE G, VAN RANST M, SCIOT R et al.: Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N. Engl. J. Med (2005) 353:362-368.
93. PADGETT BL, WALKER DL: Prevalence of antibodies in human sera against JC virus, an isolate from a case of progressive multifocal leukoencephatopathy. J. Infect. Dis. (1973) 127:467-470.
94. YOUSRY TA, MAJOR EO, RYSCHKEWITSCH C et al.: Evaluation of patients created with natalizumab for progressive multifocal leukoencephalopathy. N. Engl. J. Med (2006) 354:924-933.
95. GURTNER GC, DAVIS V, LI H, McCOY MJ, SHARP A, CYBULSKY MI: Targeted disruption of the murine VCAM-1 gene: essential role of VCAM-1 in chorioallantoic fusion and placentation. Genes Dev. (1995) 9:1-14.
96. KWEE L, BALDWIN S, STEWART CS, BUCK CA, LABOW MA: Defective development of embryonic and extraembryonic circulatory systems in vascular cell adhesion molecule (VCAM-1) deficient mice. Development (1995) 121:489-503.
97. YANG JT, RAYBURN H, HYNES RO: Cell adhesion events by α4 integrins are essential in placental and cardiac development. Development (1995) 121:549-560.
98. SPENCE S, VETTER C, HAGMANN WK et al.: Effects of VLA-4 antagonists in rat whole embryo culture. Teratology (2002) 65:26-37.
99. CROFTS F, PINO M, DELISE B et al.: Different embryo-fetal toxicity effects for three VLA-4 antagonists. Birth Defects Res. B Dev. Reprod. Toxicol. (2004) 71:55-68.
100. CROFTS F, ROHATAGI S, PINO M et al.: Critical period for a teratogenic VLA-4 antagonist: Developmental effects and comparison of embryo drug concentrations of teratogenic and non-teratogenic VLA-4 antagonists. Birth Defects Res. B Dev. Reprod. Toxicol. (2004) 71:69-79.
101. MILLER LJ, SCHWARTING R, SPRINGER TA: Regulated expression of the Mac-1, LFA-1, p150,95 glycoprotein family during leukocyte differentiation. J. Immunol. (1996) 137:2891-2900.
102. SHORTMAN K, LIU YJ: Mouse and human dendritic cell subtypes. Nat. Rev. Immunol. (2002) 2:151-161.
103. 2, binds preferentially to ICAM-3. Immunity (1995) 3:683-690.
104. 2 integrin is expressed on human eosinophils and functions as an alternative ligand for vascular cell adhesion molecule 1 (VCAM-1). J. Exp. Med. (1998) 188:2187-2191.
105. DUSTIN MI, SPRINGER TA: Lymphocyte function-associated antigen-1 (LFA-1) interaction with intercellular adhesion molecule-1 (ICAM-1) is one of at least three mechanisms for lymphocyte adhesion to cultured endothelial cells. J. Cell Biol. (1988) 107:321-331.
106. DIAMOND MS, STAUNTON DE, DE FOUGEROLLES AR et al.: ICAM-1 (CD54): a counter-receptor for Mac-1 (CD11b/CD18). J. Cell Biol. (1990) 111:3129-3139.
107. DIAMOND MS, GARCIA-AGUILAR J, BICKFORD JK, CORBI AL, SPRINGER TA: The I domain is a major recognition site on the leukocyte integrin Mac-1 (CD11b/CD18) for four distinct adhesion ligands. J. Cell Biol. (1993) 120:1031-1043.
108. STAUNTON DE, DUSTIN ML, SPRINGER TA: Functional cloning of ICAM-2, a cell adhesion ligand for LFA-1 homologous to ICAM-1. Nature (1989) 339:61-64.
109. XIE J, LI R, KOTOVUORI P, VERMOT-DESROCHES C et al.: Intercellular adhesion molecule-2 (CD 102) binds to the leukocyte integrin CD11b/CD18 through the A domain. J. Immunol. (1995) 155:3619-3628.
110. SHANG XZ, ISSEKUTZ AC: Contribution of CD1la/CD18, CD11b/CD18, ICAM-1 (CD54) and -2 (CD 102) to human monocyte migration through endothelium and connective tissue fibroblast barriers. Eur. J. Immunol. (1998) 28:1970-1979.
111. ISSEKUTZ AC, ROWTER D, SPRINGER TA: Role of ICAM-1 and ICAM-2 and alternate CD11/CD18 ligands in neutrophil transendothelial migration. J. Leukoc. Biol. (1999) 65:117-126.
112. DE FOUGEROLLES AR, SPRINGER TA: Intercellular adhesion molecule 3, a third adhesion counter-receptor for lymphocyte function associated molecule 1 on resting lymphocytes. J. Exp. Med. (1992) 175:185-190.
113. TIAN L, KILGANNON R YOSHIHARA Y et al.: Binding of T lymphocytes to hippocampal neurons through ICAM-5 (telencephalin) and characterization of its interaction with the leukocyte in regrin CD11a/CD18. Eur. J. Immunol. (2000) 30:810-818.
114. YANG J, LINDSBERG PJ, HUKKANEN V, SELJELID R, GAHMBERG CG, MERI S: Differential expression of cytokines (IL-2, IFN-γ, IL-10) and adhesion molecules (VCAM-1, LFA-1, CD44) between spleen and lymph nodes associates with remission in chronic relapsing experimental autommune encephalomyelitis. Scand. J. Immunol. (2002) 56:286-293.
115. MICKLEM KJ, SIM RB: Isolation of complement-fragment-iC3b-binding proteins by affinity chromatography. The identification of p 150,95 as an iC3b-binding protein. Biochem. J. (1985) 231:233-236.
116. LOIKE JD, SODEIK B, CAO L et al.: CD11c/CD18 on neutrophils recognizes a domain at the N terminus of the A α chain of fibrinogen. Proc. Natl. Acad. Sci. USA (1991) 88:1044-1048.
117. 2 integrin LFA-1 involved in transendothelial migration of leukocytes. Nat. Immunol. (2002) 3:151-158.
118. SANTOSO S, SACHS UJ, KROLL H et al.: The junctional adhesion molecule 3 (JAM-3) on human platelets is a counterreceptor for the leukocyte integrin Mac-1. J. Exp. Med. (2002) 196:679-691.
119. ARNAOUT MA, PITT J, COHEN HJ, MELAMED J, ROSEN FS, COLTEN HR: Deficiency of a granulocyte-membrane glycoprotein (gp 150) in a boy with recurrent bacterial infections. N. Engl. J. Med. (1982) 306:693-699.
120. ANDERSON DC, SCHALMSTEIG FC, FINEGOLD MJ et al.: The severe and moderate phenotypes of heritable Mac-1, LFA-1 deficiency: their quantitative definition and relation to leukocyte dysfunction and clinical features. J. Infect. Dis. (1985) 152:668-689.
121. ANDERSON DC, SPRINGER TA: Leukocyte adhesion deficiency: an inherited defect in the Mac-1, LFA-1, and p150-95 glycoproteins. Ann. Rev. Med. (1987) 38:175-183.
122. SPRINGER TA, THOMPSON WS, MILLER LJ, SCHMALSTIEG FC, ANDERSON DC: Inherited deficiency of the Mac-1, LFA-1, p150,95 glycoprotein family and its molecular basis. J. Exp. Med. (1984) 160:1901-1918.
123. CROWLEY CA, CURNUTTE JT ROSIN RE et al.: An inherited abnormality of neutrophil adhesion. Its genetic transmission and its association with a missing protein. N. Engl. J. Med. (1980) 302:1163-1168.
124. BOWEN TJ, OCHS HD, ALTMAN LC et al: Severe recurrent bacterial infections associated with defective adherence and chemotaxis in two patients with neutrophils deficient in a cell-associated glycoprotein. J. Pediatr. (1982) 101:932-940.
125. WACHOLTZ MC, PATEL SS, LIPSKY PE: Leukocyte function-associated antigen 1 is an activation molecule for human T cells. J. Exp. Med. (1989) 170:431-448.
126. HOURMANT M, BEDROSSIAN J, DURAND D et al.: A randomized multicenter trial comparing leukocyte function-associated antigen-1 monoclonal antibody with rabbit antithymocyte globulin as induction treatment in First kidney transplantations. Transplantation (1996) 62:1565-1570.
127. CHIN YH, FALANGA V, STREILEIN JW, SACKSTEIN R: Lymphocyte recognition of psoriatic endothelium: evidence for a tissue-specific receptor/ligand interaction. J. Invest. Dermatol. (1989) 93:82S-87S.
128. SACKSTEIN R, FALANGA V, STREILEIN JW, CHIN YH: Lymphocyte adhesion to psoriatic dermal endothelium is mediated by a tissue-specific receptor/ ligand interaction. J. Invest. Dermatol. (1988) 91:423-428.
129. 2-integrins. J. Am. Acad. Dermatol. (1992) 27:383-388.
130. HORROCKS C, DUNCAN JI, OLIVER AM, THOMSON AW: Adhesion molecule expression in psoriatic skin lesions and the influence of cyclosporin A. Clin. Exp. Immunol. (1991) 84:157-162.
131. GRIFFITHS CE, VOORHEES JJ, NICKOLOFF BJ: Characterization of intercellular adhesion molecule-1 and HLA-DR expression in normal and inflamed skin: modulation by recombinant γ interferon and tumor necrosis factor. J. Am. Acad. Dermatol. (1989) 20:617-629.
132. ZEIGLER M, CHI Y, TUMAS DB, BODARY S, TANG H, VARANI J: Anti-CD11a ameliorates disease in the human psoriatic skin-SCID mouse transplant model: comparison of antibody to CD11a with cyclosporin A and clobetasol propionate. Lab. Invest. (2001) 81:1253-1261.
133. LEBWOHL M, TYRING SK, HAMILTON TK et al.: A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N. Engl. J. Med. (2003) 349:2004-2013.
134. LINDSLEY HB, SMITH DD, COHICK CB, KOCH AE, DAVIS LS: Proinflammatory cytokines enhance human synoviocyte expression of functional intercellular adhesion molecule-1 (ICAM-1). Clin. Immunol. Immunopathol. (1993) 68:311-320.
135. BULLARD DC, HURLEY LA, LORENZO I, SLY LM, BEAUDET AL, STAITE ND: Reduced susceptibility to collagen-induced arthritis in mice deficient in intercellular adhesion molecule-1. J. Immunol. (1996) 157:3153-3158.
136. KAVANAUGH AF, DAVIS LS, NICHOLS LA et al.: Treatment of refractory rheumatoid arthritis with a monoclonal antibody to intercellular adhesion molecule 1. Arthritis Rheum. (1994) 37:992-999.
137. KAVANAUGH AF, SCHULZE-KOOPS H, DAVIS LS, LIPSKY PE: Repeat treatment of rheumatoid arthritis patients with a murine anti-intercellular adhesion molecule 1 monoclonal antibody. Arthritis Rheum. (1997) 40:849-853.
138. d/CD18, a novel leukointegrin. comparison with other integrins and their ligands. Arthritis Rheum. (1996) 39:1913-1921.
139. WATTS GM, BEURSKENS FJ, MARTIN-PADURA I et al.: Manifestations of inflammatory arthritis are critically dependent on LFA-1. J. Immunol. (2005) 174:3668-3675.
140. ERICKSON AC, COUCHMAN JR: Still more complexity in mammalian basement membranes. J. Histochem. Cytochem. (2000) 48:1291-1306.
141. HEINO J: The collagen receptor integrins have distinct ligand recognition and signaling functions. Matrix Biol. (2000) 19:319-323.
142. PROCKOP DJ, KIVIRIKKO KI. Collagens: molecular biology, diseases, and potentials for therapy. Ann. Rev. Biochem. (1995) 64:403-434.
143. 1. Eur. J. Biochem. (1993) 215:151-159.
144. 1. J. Biol. Chem. (1994) 269:22811-22816.
145. 101 domains. J. Biol. Chem. (2001) 276:48206-48212.
146. SCHWARZBAUER J: Basement membranes: putting up the barriers. Curr. Biol. (1999) 9:R242-R244.
147. HYNES RO: Integrins: versatility, modulation, and signalling in cell adhesion. Cell (1992) 69:11-25.
148. 1 integrin is expressed during neointima formation in rat arteries and mediates collagen matrix reorganization. J. Clin. Invest. (1996) 97:2469-2477.
149. 1 integrin in wound contraction. A quantitative analysis of liver myofibroblasts in vivo and in primary culture. J. Biol. Chem. (1997) 272:30911-30917.
150. 1 integrin in vitro and angiogenesis in vivo. Cancer Res. (2003) 63:2020-2023.
151. 1 mediates a unique collagen-dependent proliferation pathway in vivo. J. Cell Biol. (1998) 142:587-594.
152. RAO WN, HALES JM, CAMP RD: Potent costimulation of effector T lymphocytes by human collagen type I. J. Immunol. (2000) 165:4935-4940.
153. 1 integrins. J. Cell Biol. (1995) 131:1903-1915.
154. 1 by homologous recombination permits normal murine development but gives rise to a specific deficit in cell adhesion. Dev. Biol. (1996) 175:301-313.
155. HEMLER ME, JACOBSON JG, BRENNER MB, MANN D, STROMINGER JL: VLA-1: a T cell surface antigen which defines a novel late stage of human T cell activation. Eur. J. Immunol. (1985) 15:502-508.
156. 1 (VLA-1) integrin expression by lipopolysaccharide and inEerferon-γ. Eur. J. Immunol. (1995) 25:2701-2705.
157. 1 in models of hypersensitivity and arthritis. J. Clin. Invest. (2000) 105:721-729.
158. HEMLER ME, GLASS D, COBLYN JS, JACOBSON JQ: Very late activation antigens on rheumatoid synovial fluid T lymphocytes. Association with stages of T cell activation. J. Clin. Invest. (1986) 78:696-702.
159. HANSSON GK, HOLM J, JONASSON L: Detection of activated T lymphocytes in
160. CORRIGAN CJ, HARTNELLA, KAY AB: T lymphocyte activation in acute severe asthma. Lancet (1988) 1:1129-1132.
161. ABRAHAM WM, AHMED A, SEREBRIAKOV I et al.: A monoclonal antibody to α1β1 blocks antigen-induced airway responses in sheep. Am. J. Respir. Crit. Care Med. (2004) 169:97-104.
162. 4 integrins in gut mucosal injury of graft-versus-host disease. Int. Immunol. (1995) 7:1183-1189.
163. 1 integrin in dogs. Immunobiology (2000) 202:239-253.
164. MEHARRA EJ, SCHON M, HASSETT D, PARKER C, HAVRAN W, GARDNER H: Reduced gut intraepithelial lymphocytes in VLA1 null mice. Cell Immunol. (2000) 201:1-5.
165. 1 integrins. J. Biol. Chem. (1999) 274:32182-32191.
166. 1 regulates intestinal inflammation in experimental cotitis. J. Clin. Invest. (2002) 110:1773-1782.
167. 1 in TNBS-induced cotiris. Immunity (2002) 17:769-780.
168. BOEHNCKE WH, KELLNER I, KONTER U, STERRY W: Differential expression of adhesion molecules on infiltrating cells in inflanimatory dermatoses. J. Am. Acad. Dermatol. (1992) 26:907-913.
169. CONRAD C, BOYMAN O, DE FOUGEROLLES A, KOTELIANSKI V, GARDNER H, NESTLE FO: VLA-1 dependent intraepidermal T cell expansion is necessary for the development of psoriasis. Abstracts of Papers, 34th Annual European Societyfor Dermatological Research Meeting, Vienna, Austria (11 September 2004.) (Abstract 152).
170. BOYMAN O, HEFTI HP, CONRAD C, NICKOLOFF BJ, SUTER M, NESTLE FO: Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor-α. J. Exp. Med. (2004) 199:731-736.
171. 1 integrin I domain. Biochemistry (1999) 38:8280-8288.
172. WELZENBACH K, HOMMEL U, WEITZ-SCHMIDT G: Small molecule inhibitors induce conformational changes in the I domain and the I-like domain of lymphocyte function-associated antigen-1. Molecular insights into integrin inhibition. J. Biol. Chem. (2002) 277:10590-10598.
173. KOLAKOWSKI GR, BJORNSON KL, JUDKINS A et al.: Identification of the potent small molecule inhibitors of VLA-1 inregrin. Abstracts of Papers, 231st ACS National Meeting, Washington, DC, USA, (26 - 30 March 2006).
174. 1 itegrin to vascular thrombosis in vivo. Blood (2003) 102:3652-3657.
175. GARDNER H, BROBERG A, POZZI A, LAATO M, HEINO J: Absence of integrin α1β1 in the mouse causes loss of feedback regulation of collagen synthesis in normal and wounded dermis. J. Cell Sci. (1999) 112(Part 3):263-272.
176. 1 leads to severe glomerulosclerosis after glomerular injury. Am. J. Pathol. (2004) 165:617-630.
177. -/- mice. Arterioscler Thromb. Vasc. Biol. (2005) 25:1917-1924.
178. BEN HORIN S, BANK I: The role of very late antigen-1 in immune-mediated inflammation. Clin. Immunol. (2004) 113:119-129.
179. 1 integrin VLA-1 regulates CD8 T cell-mediated immune protection against heterologous influenza infection. Immunity (2004) 20:167-179.
180. WOODSIDE DG: Dancing with multiple partners. Sci. STKE (2002) 2002:E14.
181. LIU S, CALDERWOOD DA, GINSBERG MH: Integrin cytoplasmic domain-binding proteins. J. Cell Sci. (2000) 113:3563-3571.
182. HORWITZ A, DUGGAN K, BUCK CA, BECKERLE MC, BURRIDGE K: Interaction of plasma membrane fibronectin receptor with talin-a transmembrane linkage. Nature (1986) 320:531-533.
183. 1 integrin subunit in vitro. J. Cell Biol, (1990) 111:721-729.
184. SCHALLER MD, OTEY CA, HILDEBRAND JD, PARSONS JT: Focal adhesion kinase and paxillin bind to peptides mimicking β integrin cytoplasmic domains. J. Cell Biol. (1995) 130:1181-1187.
185. WOODSIDE DG, OBERGFELL A, LENG L et al.: Activation of Syk protein tyrosine kinase through interaction with integrin β cytoplasmic domains. Curr. Biol. (2001) 11:1799-1804.
186. ARIAS-SALGADO EG, LIZANO S, SARKAR S, BRUGGE JS, GINSBERG MH, SHATTIL SJ: Src kinase activation by direct interaction with the integrin β cytoplasmic domain. Proc. Natl. Acad. Sci. USA (2003) 100:13298-13302.
187. 11b subunit and regulates signaling. J. Biol. Chem. (2004) 279:33039-33042.
188. CALDERWOOD DA, FUJIOKA Y, DE PEREDA JM et al.: Integrin β cytoplasmic domain interactions with phosphoryrosine-binding domains: a structural prototype for diversity in integrin signaling. Proc. Natl. Acad. Sci. USA (2003) 100:2272-2277.
189. 4 integrins modifies integrin-dependent biological responses. Nature (1999) 402:676-681.
190. BIANCHI E, DENTI S, GRANATA A et al.: Integrin LFA-1 interacts with the transcriptional co-activator JAB1 to modulate AP-1 activity. Nature (2000) 404:617-621.
191. 1-dependent cell migration. J. Cell Biol. (2003) 162:731-741.
192. 4 cytoplasmic domain to regulate the reversible binding of paxillin. J. Biol. Chem. (2003) 278:34845-34853.
193. 4 integrin-paxillin-Arf-GAP complex restricts Rac activation to the leading edge of migrating cells. Nat. Cell Biol. (2005) 7:343-352.
194. 4 integrin-paxillin interaction selectively impairs mononuclear leukocyte recruitment to an inflammatory site. J. Clin. Invest. (2006) 116:715-723.
195. 4 binding: a well-documented use of positional scanning libraries. Chem. Biol. (2002) 9:1219-1226.
196. BOUGIE DW, WILKER PR, WUITSCHICK ED et al.: Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GP11b/Illa. Blood (2002) 100:2071-2076.
197. BEDNAR B, COOK JJ, HOLAHAN MA et al.: Fibrinogen receptor antagonist-induced thrombocytopenia in chimpanzee and rhesus monkey associated with preexisting drug-dependent antibodies to platelet glycoprotein 11b/111a. Blood (1999) 94:587-599.
198. MOCHLY-ROSEN D, GORDO AS: Anchoring proteins for protein kinase C: a means for isozyme selectivity. FASEB J. (2000) 12:35-42.
199. MOCSAI A, ZHOU M, MENG F, TYBULEWICZ VL, LOWELL CA: Syk is required for integrin signaling in neutrophils. Immunity (2002) 16:547-558.
200. KEANE J, GERSHON S, WISE RP et al.: Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. N. Engl. J. Med. (2001) 345:1098-1104.
201. PAGNOUX C, HAYEM G, ROUX F et al.: JC virus leukoencephalopathy complicating Wegener's granulomatosis. Joint Bone Spine (2003) 70:376-379.
202. SCHNEIDER F: [Progressive multifocal leukoencephalopathy as a cause of neurologic symptoms in Sharp syndrome] Z. Rheumatol. (1991) 50:222-224.